Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-06-27
2006-06-27
Jones, Dwayne (Department: 1614)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S269000, C514S272000, C514S274000, C514S275000, C544S242000, C544S297000, C544S298000, C544S315000, C544S317000, C544S322000
Reexamination Certificate
active
07067664
ABSTRACT:
Corticotropin-releasing factor (CRF) antagonists having the formulaewherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16and R17are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
REFERENCES:
patent: 4605642 (1986-08-01), Rivier et al.
patent: 4839353 (1989-06-01), Hosoi et al.
patent: 5063245 (1991-11-01), Abreu et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 3145287 (1983-05-01), None
patent: 0475411 (1992-03-01), None
patent: 0482804 (1997-01-01), None
patent: 0773023 (1997-05-01), None
patent: 0951906 (1999-10-01), None
patent: 1040831 (2000-04-01), None
patent: 1059100 (2000-12-01), None
patent: WO9413676 (1994-06-01), None
patent: WO 9510506 (1995-04-01), None
patent: 9533750 (1995-12-01), None
patent: WO 95/33750 (1995-12-01), None
Chalmers, D.T., et al., Corticotrophin-releasing factors molecular biology of drug design. Trends in Pharmacological Sciences, (1996), vol. 17, pp. 166-172.
Cossey, A. L., et al. “Pyridines & Pyridinium Salts from Cyanoacetamides” Australian Journal of Chem. (1976), 29, p. 1039-50.
Owens, et al., “Physiology and Pharmacology of Corticotropin-releasing factor”, Pharm. Rev., (1991), vol. 43, pp. 425-473.
Fujikakwa, K., et al. “Herbicidal activities of phenoxypyridines”. Chemical Abstract, (1970), Abstract No. 11080v.
Fujikakwa, K., et al. “Studies on Herbicidal Activities of Phenoxypyridines”. Agr. Biol. Chemical, (1970), vol. 34, No. 1 p. 68-79.
DeSouza, E.B., “Corticotropin-releasing Factor Receptors Physiology, Pharmacology, Biochemistry & Role in Central Nervous System & Immune Disorders.”, (1995), vol. 20, No. 8, pp. 789-819.
Fackelmann, K.A. & Raloff, J. “Psychological Street Linked to Cancer”, Science News, (Sep. 25, 1993), vol. 144, p. 196.
Lyons, M.K., et al., “Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury”, Brain Research, (1991), vol. 545, Issue 1-2, pp. 339-342.
Stratakis, C.A. & Chrousos, G. P., “Hypothalamic Hormones, GnRH, TRH, CHRH, SRIF, CRH, & Dopamine, Endocrinology” Basic & Clinical Principles, (1997), pp. 185-209 (Humana Press, Tofowa, NJ, 1997).
Strijbos, P. J. L. M., et al. Brain Research, vol. 656, (1991), pp. 405-408.
Robins, M.J., et al., Can. J. Chem. (1977), vol. 55, pp. 1252-1259.
Delta Sleep-Inducing Peptide Response to Human Corticotropin-Releasing Hormone (CRH) in Major Depressive Disodr, 1998 Soc. Biol. Psychiatry—Lesch, Widerlov, Ekman, Laux, Schulte, Pfuller,Beckman.
Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders, Endocrinology and Metabolism Clinics of N.A. 31 (2002) 15-36—Vgontzas, Chrousos.
Antidepressant-like effects of CP-154,526, a selective CRF, receptor antagonist, European Journal of Pharmacology 323 (1997) 21-26, Mansback, Brooks, Chen.
CP-154,526: A potent& selective nonpeptide antagonist of corticotropin releasing fctr receptors, Proc. Natl Acad Sci.vol. 93, pp. 10477-10482, Sep. 1996 Pharmacology—Shultz, Mansbach, Sprouse, Braselton, Collins, Corman, Dunaiskis, Faraci, Schmidt, Seeger, Seymour, Tingley, Winston, Chen,Heym.
Corticotropin-releasing hormone microinfusion in central anygdala diminishes a cardiac parasy mpathetic otflow undr stress-free conditns, Brain Research 625(1993)219-229pp. 27-35- Bohus, Koolhaas.
Interactions between Testicular Serotoninergic, Catecholaminergic, and Corticotropin-Releasing Hormone Systems Modulating cAMP and Testosterone Production in the Golden Hamster, Neuroendocrinology 2002:76:35-46- Frungieri, Zitta, Pignataro, Gonzalez-Calvar, Calandra.
The Role of the CRH Type 1 Rcptr in Autonomic Responses to Corticotropin-Releasing Hormone in the Rat,Neuropsychopharmacology 2000-vol. 22,No. 4- Nijsen,Croiset,Stam,Bruijnzeel,Diamant,Wied,Wiegant.
Dble-blnd, randomized trl for the cntl of delayed emesis in pnts receiving cisplatin: Comparison of placebo vs. adrenocorticotropic hormone (ACTH), Anls of Oncology3:481-485 1992- Passalacque, Cocconi, Bella,Monici,Michiara,Bandini,Bacchi.
Dble-Blnd, Multicenter, Randomized Trial to Cmpre the Effect of 2 Dses of Adrenocorticotropic Hormone Vs Placebo in Controlling Delayed Emesis After High-Dose Cisplatin in Adult Patients with Cancer, Journal of Clinical Oncology, vol. 15, No. 6(Jun.) 1997 pp. 2467-2473—Passalacqua, Cocconi, Caminiti, Silingordi, Bella, Bichisao, Michiara, Malavasi, Donati, Di Costanzo, Rocca, Sarra, Scaglione, Fraschini.
Hormonal Responses of Metoclopramide- Treated Subjects experiencing Nausea or emesis During Parabolic Flight, Aviation, Space and Environmental Medicine, Sep. 1987- Kohl.
Chhabria etal, Heterocycles, vol. 51, No. 11, 1999.
Kamel et al, Pharmazie 1990, 45 (2), 139-140.
Demina et al., Khim. Farm. Zh., 1993, 27(7), pp. 34-35 (with English summary).
Demina et al., Geterotsikl Soedin, 192 (11), pp. 1506-1508 (with English summary).
Jones Dwayne
Ladas and Parry LLP
Pfizer Inc.
Pfizer Products Inc.
LandOfFree
Corticotropin releasing factor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Corticotropin releasing factor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Corticotropin releasing factor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634133